

**ROLE OF GALANIN AND ITS ANTAGONISTS IN  
EXPERIMENTAL ACUTE PANCREATITIS**

A thesis submitted for the degree of Doctor of Philosophy

By

**Mayank Bhandari**

M.B.B.S., M.S.

Pacreatobiliary Research Group  
Department of General and Digestive Surgery  
School of Medicine  
Faculty of Health Sciences  
Flinders University  
Australia

October 2008

## TABLE OF CONTENTS

<b>Summary of Thesis.....</b>	<b>1</b>
<b>Publications from the studies in this thesis.....</b>	<b>4</b>
Manuscripts.....	4
Abstracts and Conference Presentations.....	4
<b>Declaration.....</b>	<b>8</b>
<b>Acknowledgements.....</b>	<b>9</b>
<b>Abbreviations.....</b>	<b>11</b>
<b>Structure of thesis.....</b>	<b>13</b>
<b>Chapter 1: Introduction.....</b>	<b>16</b>
1.1 Brief history of the pancreas and acute pancreatitis.....	16
1.2 Anatomy of the human pancreas.....	19
1.2.1 Anatomical relations of pancreas.....	21
1.2.2 Pancreatic ducts.....	21
1.2.3 Arterial supply of the pancreas.....	21
1.2.4 Lymphatic drainage of the pancreas.....	22
1.2.5 Nerve supply.....	23
1.2.6 Embryology of the pancreas.....	25
1.3 Morphology of the pancreas.....	25
1.3.1 Exocrine pancreas.....	25
1.3.2 Endocrine pancreas.....	26
1.3.3 Insulo–acinar interaction.....	28
1.4 Physiology of the pancreas.....	29
1.4.1 The Exocrine pancreas.....	29
1.4.2 Regulation of pancreatic secretion.....	31
1.4.3 Stimulation of bicarbonate secretion by secretin.....	32
1.4.4 Endocrine Pancreas.....	32
1.5 Galanin.....	34
1.5.1 Discovery of galanin.....	34
1.5.2 Structure.....	34
1.5.3 Synthesis of endogenous galanin.....	35
1.5.4 Distribution.....	35
1.5.5 Pancreatic localization of galanin.....	36
1.5.6 Actions.....	37

1.5.7	Galanin receptors and ligands.....	39
1.6	Acute Pancreatitis.....	43
1.6.1	Epidemiology.....	44
1.6.2	Classification of AP.....	44
1.6.3	Severity of AP.....	45
1.6.4	Etiology.....	46
1.6.5	Pathophysiology of AP.....	48
1.6.6	Inflammatory mediators in AP.....	52
1.6.7	Pancreatic vascular changes in AP.....	54
1.6.8	Neural mechanisms in AP.....	56
1.6.9	Pancreatic vascular perfusion (PVP) and AP.....	57
1.6.10	Markers of pancreatic injury.....	59
1.7	Experimental models of AP.....	61
1.7.1	Historical review of experimental models of AP.....	61
1.7.2	In vivo techniques to induce experimental AP.....	62
1.7.3	Ex vivo techniques.....	66
1.8	Project rationale.....	67
1.9	Overall hypothesis.....	67
1.9.1	Specific hypotheses.....	67
1.9.2	Aims.....	68

**Chapter 2: Effects of exogenous galanin and galantide administration in a possum model of mild AP.....70**

2.1	Introduction.....	70
2.1.1	Specific Hypotheses.....	70
2.2	Specific aims.....	70
2.3	Methodological considerations.....	71
2.4	Methods.....	71
2.4.1	Possums and animal ethics approval.....	71
2.4.2	Pharmaceutical agents.....	72
2.4.3	Experiment set up.....	73
2.4.4	Protocol for inducing AP and collection of data.....	74
2.4.5	Protocol for prophylactic administration of galanin or galantide.....	75
2.4.6	Protocol for therapeutic administration of galantide.....	75
2.4.7	Study groups.....	76
2.4.8	Parameters measured.....	76
2.4.9	Histological examination.....	77
2.4.10	Analysis.....	79

2.4.11	Statistical analysis.....	80
2.5	Results.....	80
2.5.1	Blood pressure.....	80
2.5.2	Pancreatic duct pressure.....	80
2.5.3	Plasma enzyme activities.....	81
2.5.4	Histology.....	82
2.5.5	Urine output.....	84
2.6	Discussion.....	85
2.7	Conclusion.....	90

**Chapter 3: Effects of galanin and galantide on Pancreatic Vascular Perfusion (PVP) in the possum model of mild AP.....102**

3.1	Introduction.....	102
3.2	Specific hypothesis.....	103
3.3	Aim.....	103
3.4	Methods.....	103
3.4.1	Pharmaceutical agents.....	104
3.4.2	Protocol for experimental setup.....	104
3.4.3	Pancreatic vascular perfusion measurement.....	104
3.4.4	Induction of acute pancreatitis.....	105
3.4.5	Parameters measured.....	105
3.4.6	Analysis.....	105
3.4.7	Statistical analysis.....	106
3.5	Results.....	107
3.5.1	Blood prssure.....	107
3.5.2	Pancreatic duct pressure.....	107
3.5.3	Pancreatic vascular perfusion.....	107
3.5.4	Pancreatic vascular conductance.....	108
3.5.5	Plasma enzymes.....	108
3.6	Discussion.....	108
3.7	Conclusion.....	112

**Chapter 4: Effects of galanin and galantide administration on basal and hyperstimulated pancreatic exocrine secretion.....116**

4.1	Introduction.....	116
4.2	Hypothesis.....	116
4.3	Aims.....	116
4.4	Methods.....	116

4.4.1	Pharmaceutical agents.....	117
4.4.2	Basal pancreatic exocrine secretion study.....	117
4.4.3	Hyperstimulated pancreatic exocrine secretion study.....	118
4.4.4	Study groups.....	118
4.4.5	Parameters analyzed.....	119
4.4.6	Analysis.....	120
4.4.7	Statistical analysis.....	120
4.5	Results.....	120
4.5.1	Basal exocrine secretion.....	120
4.5.2	Hyperstimulated exocrine secretion.....	120
4.5.3	Pancreatic amylase and lipase activities.....	121
4.5.4	Pancreatic total protein secretion.....	121
4.6	Discussion.....	121
4.7	Conclusion.....	125

**Chapter 5: Effects of galanin and galantide administration on AP in the caerulein mouse model.....132**

5.1	Introduction.....	132
5.2	Hypothesis.....	133
5.3	Aim.....	134
5.4	Methods.....	134
5.4.1	Animal ethics approval.....	134
5.4.2	Animals.....	134
5.4.3	Pharmaceutical agents.....	135
5.4.4	Orbital sinus bleeding.....	135
5.4.5	Protocol for induction of AP.....	135
5.4.6	Prophylactic protocol.....	136
5.4.7	Therapeutic protocol.....	137
5.4.8	Study groups.....	137
5.4.9	Pancreas harvest.....	137
5.4.10	Parameters measured.....	138
5.4.11	Statistical analysis.....	141
5.5	Results.....	141
5.5.1	Plasma amylase and lipase activity.....	141
5.5.2	Pancreatic MPO activity.....	142
5.5.3	Histological assessment.....	143
5.6	Discussion.....	145
5.7	Conclusion.....	150

**Chapter 6: Role of endogenous galanin in AP.....160**

6.1	Hypothesis.....	160
6.2	Aim.....	161
6.3	Methods.....	161
6.3.1	Animal ethics approval.....	161
6.3.2	Animals.....	161
6.3.3	Pharmaceutical agents.....	162
6.3.4	Protocol for induction of AP.....	162
6.4	The post-treatment pancreas harvest.....	162
6.4.1	Study groups.....	162
6.4.2	Parameters measured.....	162
6.4.3	MPO assay.....	163
6.4.4	Protein assay.....	163
6.4.5	Statistical analysis.....	164
6.5	Results.....	164
6.5.1	Plasma amylase and lipase activities.....	164
6.5.2	Histological assessment.....	165
6.5.3	Pancreatic MPO activity.....	167
6.6	Discussion.....	167

**Chapter 7: Effects of M35, M40 and C7 in caerulein mouse model of mild AP.....174**

7.1	Introduction .....	174
7.2	Hypothesis .....	174
7.3	Aim .....	175
7.4	Methods.....	175
7.4.1	Animal ethics approval .....	175
7.4.2	Animals.....	175
7.4.3	Pharmaceutical agents.....	175
7.4.4	Protocol for induction of AP.....	175
7.4.5	Study groups.....	176
7.4.6	Parameters measured and statistical analyses.....	176
7.5	Results.....	177
7.5.1	Plasma enzymes.....	177
7.5.2	MPO activity.....	179
7.5.3	Histological assessment.....	180

7.6	Discussion.....	183
7.7	Conclusion.....	187
<b>Chapter 8: General discussion.....</b>		<b>194</b>
8.1	Overview of findings.....	194
8.2	General conclusions and future studies.....	195
<b>References.....</b>		<b>204</b>

## **SUMMARY OF THESIS**

The broad aim of the studies described in this thesis was to evaluate the role of neuropeptide galanin in acute pancreatitis (AP). Treatment of AP is mainly symptomatic and supportive and no definitive pharmacological therapy for this disease is currently available.

There are a number of studies in animal models of AP which demonstrate beneficial effect of a pharmacological agent in the management of AP. But most of these studies are limited to single species. The studies presented in the thesis evaluate the role of galanin and several of its antagonists in experimental AP in two different species. The initial part of the experimental work was performed in the possums, using a well established model of AP in the laboratory. Later, the experimental work has been carried out in the mouse.

The overall hypothesis was that galanin plays a major role in the onset and/or progression of AP.

In Chapter 2, the effect galanin or galantide administration, before and after AP induction on severity of AP in the possum model is described. The studies demonstrated that galantide decreased various indices of AP when administered prophylactically and therapeutically.



Chapter 3 outlines studies to determine if administration of galanin or galantide alters pancreatic vascular perfusion (PVP) during AP in the possum model. These studies suggested that in AP there is an initial fall in PVP, which is exacerbated by administration of galanin prior to onset of AP. Conversely, galantide administration prevented this decrease in PVP, and was associated with a rise in PVP through out the duration of the experiment.

Chapter 4 describes preliminary studies on effect of galanin and galantide on pancreatic exocrine secretion. These demonstrated that galantide decreased hyperstimulated pancreatic exocrine secretion, but had no effect on the basal secretion.

The subsequent studies are carried out using the caerulein mouse model of AP. The hypothesis has been tested in three different strains of mice, including a galanin gene knock-out (KO) strain.

Chapter 5 outlines the effect galanin or galantide administration, before and after AP induction on the severity of AP in the caerulein mouse model. These studies revealed that galantide administration both prophylactically and therapeutically decreased the severity of AP in the mouse.

In Chapter 6, the galanin gene KO were used to further test the hypothesis. These studies revealed that AP was less severe in the galanin KO mice, thereby suggesting a role for endogenous galanin in the onset and/or progression of AP.

Chapter 7 describes the effects of various galanin antagonist on the severity of AP in the caerulein mouse model. These studies revealed that galantide and M35 have beneficial effects in AP, i.e. reduced the indices of AP, whereas C7 and M40 had complex effects.

Chapter 8 provides an overview of findings and discussion of their broader ramifications with future recommendations.

Overall, the studies have demonstrated that galanin plays a major role in AP and galanin antagonists may be of potential therapeutic value in the management of AP.

## **PUBLICATIONS FROM THE STUDIES IN THIS THESIS**

### **Manuscripts**

Brooke-Smith ME , Carati CJ, **Bhandari M**, Toouli J, Saccone GTP. Galanin in the regulation of pancreatic vascular perfusion. Accepted for publication in Pancreas, Jan 2008.

Due to intellectual property issues publications were delayed. Presently the following manuscripts are being prepared

**Bhandari M**, Thomas AC, Carati CJ, Toouli J, Saccone GTP. Galanin antagonism modifies hyperenzymemia and pancreatic vascular perfusion (PVP) changes induced by acute pancreatitis (AP) in a possum model.

**Bhandari M**, Thomas AC, Carati CJ, Kawamoto M, Toouli J, Saccone GTP. Galanin antagonism ameliorates hyperenzymemia and pancreatic necrosis in caerulein-induced acute pancreatitis in the mouse.

**Bhandari M**, Kawamoto M, Thomas AC, Carati CJ, Toouli J, Saccone GTP. The galanin knockout mouse is less susceptible to caerulein-induced acute pancreatitis.

### **Abstracts and Conference Presentations**

#### **Abstracts**

Saccone GTP, London JA, Woods CM, **Bhandari M**, Carati CJ, Brooke-Smith ME, Toouli J. Acute ethanol modulates pancreatic vascular perfusion in the Australian possum. Proceeding of the Falk Symposium No 143, poster # 42, 2004.

London JA, Woods CM, **Bhandari M**, Carati CJ, Brooke-Smith ME, Toouli J, Saccone GTP. Intragastric but not intravenous ethanol decreases pancreatic vascular perfusion in the Australian possum. Pancreas, 29 (4), 327, 2004.

**Bhandari M**, Brooke-Smith ME, Carati CJ, Toouli J, Saccone GTP. Galanin reduces pancreatic vascular perfusion (PVP) in the Australian possum. Proceedings of the AHMR Congress, 517, 2004.

**Bhandari M**, Thomas AC, Carati CJ, Kawamoto M, Brooke-Smith ME, Toouli J, Saccone GTP. Galanin antagonism reduces hyperenzymemia associated with acute pancreatitis (AP) in a possum model. Gastroenterology, 130 (4; Suppl2), A-707, 2006.

**Bhandari M**, Thomas AC, Carati CJ, Kawamoto M, Brooke-Smith ME, Saccone GTP, Toouli J. Galanin antagonism reduces hyperenzymemia associated with acute pancreatitis (AP) in a possum model.

**Bhandari M**, Thomas AC, Carati CJ, Kawamoto M, Toouli J, Saccone GTP. Galanin antagonism ameliorates hyperenzymemia and pancreatic necrosis in caerulein-induced acute pancreatitis in the mouse. *J Gastroenterol Hepatol* 21 (suppl: 4), A355, 2006.

**Bhandari M**, Thomas AC, Carati CJ, Kawamoto M, Brooke-Smith ME, Saccone GTP, Toouli J. Galanin antagonism modifies acute pancreatitis (AP)-induced hyperenzymemia and pancreatic vascular perfusion changes in a possum model. *J Gastroenterol Hepatol* 21 (suppl: 4), A354, 2006.

**Bhandari M**, Thomas AC, Carati CJ, Kawamoto K, Toouli J, Saccone GTP. Galanin antagonism ameliorates caerulein-induced acute pancreatitis (AP) in a mouse model. *Pancreas*, 33 (4), 447, 2006.

**Bhandari M**, Thomas AC, Carati CJ, Kawamoto K, Toouli J, Saccone GTP. Galanin antagonism modifies hyperenzymemia and pancreatic vascular perfusion (PVP) changes induced by acute pancreatitis (AP) in a possum model. *Pancreas*, 33 (4), 447, 2006.

**Bhandari M**, Thomas AC, Carati CJ, Kawamoto K, Brooke-Smith ME, Saccone GTP, Toouli J. Galanin antagonism reduces hyperenzymemia associated with acute pancreatitis (AP) A possum model. *HPB*, 83 (Suppl 2), 56, 2006.

**Bhandari M**, Kawamoto M, Thomas AC, Carati CJ, Toouli J, Saccone GTP. The galanin knockout mouse is less susceptible to caerulein-induced acute pancreatitis. *J HPB Surgery*, in press.

Kawamoto M, **Bhandari M**, Thomas AC, Carati CJ, Toouli J, Saccone GTP. The galanin antagonist M35 but not M40 ameliorates caerulein-induced acute pancreatitis in a mouse model. *J HPB Surgery*, in press.

**Bhandari M**, Kawamoto M, Thomas AC, Carati CJ, Ormandy, CJ, Toouli J, Saccone GTP. Galanin knockout mice are less susceptible to caerulein-induced acute pancreatitis. *Gastroenterology* 132 (4), (Supplement 2), A-250, 2007.

**Bhandari M**, Kawamoto M, Thomas AC, Carati CJ, Toouli J, Saccone GTP. Galanin receptor antagonist M35: a potential pharmacological treatment for acute pancreatitis. *Gastroenterology* 132 (4), (Supplement 2), A-253, 2007.

Kawamoto M, **Bhandari M**, Thomas AC, Carati CJ, Toouli J, Saccone GTP. The galanin antagonists galantide and M35 but not M40 ameliorate caerulein-induced acute pancreatitis in mice. *Pancreatology*, in press.

## Conference Presentations

Poster - Saccone GTP, London JA, Woods CM, **Bhandari M**, Carati CJ, Brooke-Smith ME, Toouli J. (Presenter: GTP Saccone). Acute ethanol modulates pancreatic vascular perfusion in the Australian possum. The Falk Symposium No 143 (Pancreatitis: Advances in pathobiology, diagnosis and treatment), Frieberg, Germany, October, 2004.

Oral - **Bhandari M**, Brooke-Smith ME, Carati CJ, Toouli J, Saccone GTP. (Presenter: M Bhandari). Galanin reduces pancreatic vascular perfusion (PVP) in the Australian possum. AHMR Congress, Sydney, NSW, November 2004.

Poster - London JA, Woods CM, **Bhandari M**, Carati CJ, Brooke-Smith ME, Toouli J, Saccone GTP. (Presenter: GTP Saccone). Intra-gastric but not intravenous ethanol decreases pancreatic vascular perfusion in the Australian possum. APA Chicago, USA, November 2004.

Oral – **Bhandari M**, Thomas AC, Carati CJ, Toouli J, Saccone GTP. (Presenter: M Bhandari). Galanin antagonism ameliorates the severity of caerulein-induced acute pancreatitis in the mouse. Australasian pancreatic Club, Sydney, March, 2006.

Oral - **Bhandari M**, Thomas AC, Carati CJ, Kawamoto M, Brooke-Smith ME, Toouli J, Saccone GTP. (Presenter: M Bhandari). Galanin antagonism reduces hyperenzymemia associated with acute pancreatitis (AP) in a possum model. Digestive Diseases Week, Los Angeles, USA, May 2006.

Oral - **Bhandari M**, Thomas AC, Carati CJ, Kawamoto M, Brooke-Smith ME, Toouli J, Saccone GTP. (Presenter: M Bhandari). Galanin antagonism reduces hyperenzymemia associated with acute pancreatitis (AP) in a possum model. ASMR (SA Branch) annual meeting June, 2006.

Oral - **Bhandari M**, Thomas AC, Carati CJ, Kawamoto M, Brooke-Smith ME, Saccone GTP, Toouli J. (Presenter: J Toouli). Galanin antagonism reduces hyperenzymemia associated with acute pancreatitis (AP) A possum model. International Hepto Pancreato Biliary Association 10th World Congress, Edinburgh, Scotland, September, 2006.

Oral - **Bhandari M**, Thomas AC, Carati CJ, Kawamoto M, Toouli J, Saccone GTP. (Presenter: M Bhandari). Galanin antagonism ameliorates hyperenzymemia and pancreatic necrosis in caerulein-induced acute pancreatitis in the mouse. Australian Gastroenterology Week, Adelaide, SA, October 11-14, 2006.

Poster - **Bhandari M**, Thomas AC, Carati CJ, Kawamoto M, Brooke-Smith ME, Saccone GTP, Toouli J. (Presenter: M Bhandari). Galanin antagonism modifies acute pancreatitis (AP)-induced hyperenzymemia and pancreatic vascular

perfusion changes in a possum model. Australian Gastroenterology Week, Adelaide, SA, October 11-14, 2006. Poster of Merit.

Poster - **Bhandari M**, Thomas AC, Carati CJ, Kawamoto K, Toouli J, Saccone GTP. Galanin antagonism ameliorates caerulein-induced acute pancreatitis (AP) in a mouse model. (Presenter: GTP Saccone). Joint APA/IAP meeting, Chicago USA, November 2006.

Poster - **Bhandari M**, Thomas AC, Carati CJ, Kawamoto K, Toouli J, Saccone GTP. Galanin antagonism modifies hyperenzymemia and pancreatic vascular perfusion (PVP) changes induced by acute pancreatitis (AP) in a possum model. (Presenter: GTP Saccone). Joint APA/IAP meeting, Chicago USA, November 2006. Poster of distinction

Poster - **Bhandari M**, Kawamoto M, Thomas AC, Carati CJ, Toouli J, Saccone GTP. The galanin knockout mouse is less susceptible to caerulein-induced acute pancreatitis. (Presenter: J Toouli). A-PHPB, Fukuoka, Japan, March 2007.

Poster - Kawamoto M, **Bhandari M**, Thomas AC, Carati CJ, Toouli J, Saccone GTP. The galanin antagonist M35 but not M40 ameliorates caerulein-induced acute pancreatitis in a mouse model. (Presenter: J Toouli). A-PHPB, Fukuoka, Japan, March 2007.

Oral - Zotti MGT, **Bhandari M**, Thomas AC, Carati CJ, Toouli J, Saccone GTP. (Presenter: M Zotti). Galanin type 2 receptors are involved in acute pancreatitis in a mouse model. Southern Health Inaugural Research Week, Victoria, April 2007.

Poster - **Bhandari M**, Kawamoto M, Thomas AC, Carati CJ, Ormandy, CJ, Toouli J, Saccone GTP. Galanin knockout mice are less susceptible to caerulein-induced acute pancreatitis. (Presenter: J Toouli). Digestive Diseases Week, Washington DC, USA, May, 2007.

Poster - **Bhandari M**, Kawamoto M, Thomas AC, Carati CJ, Toouli J, Saccone GTP. Galanin receptor antagonist M35: a potential pharmacological treatment for acute pancreatitis. (Presenter: J Toouli). Digestive Diseases Week, Washington DC, USA, May, 2007.

Poster - Kawamoto M, **Bhandari M**, Thomas AC, Carati CJ, Toouli J, Saccone GTP. The galanin antagonists galantide and M35 but not M40 ameliorate caerulein-induced acute pancreatitis in mice. (Presenter: GTP Saccone). Digestive European Pancreatic Club, Newcastle-Gateshead, UK, July 2007.

## **DECLARATION**

I certify that this thesis does not incorporate without acknowledgement any material previously submitted for a degree or diploma in any university; and that to the best of my knowledge and belief it does not contain any material previously published or written by another person except where due reference is made in the text.

Mayank Bhandari, M.B.B.S., M.S

Date:

## **ACKNOWLEDGEMENTS**

I wish to take the opportunity to thank a number of people whose assistance has been instrumental in the studies associated with this thesis.

I am indebted to my supervisors Professor James Toouli, Associate Professor Gino Saccone and Associate Professor Colin Carati for their continuous support, encouragement, constant assistance and critical and constructive feedback during my candidature. I wish to thank them for their useful discussion and comments regarding the preparation of this thesis and associated conference presentations. I am also grateful to Professor A Thomas for his help in histological analysis of slides.

I am also grateful to Ann Schloithe for the technical expertise and advice provided by her on various aspects of surgical skills and interpretation of statistical analyses associated with these studies. The assistance and friendship of staff and students in the Pancreatobiliary Research Laboratory group was especially helpful. In particular I wish to thank Aaron Citti, Masahiko Kawamoto, Charmine Woods and Elizabeth Andrews.

I am also grateful to the staff of Departments of Pathology and Biochemistry for their cooperation in preparation of histological specimen slides and estimation of plasma pancreatic enzymes respectively.

I would especially like to mention the helpful services of the staff in the Animal house and the staff in Medical Illustration and Media, thank you all for your help.

I wish to thank Dr. C.Ormandy from Garvan Institute of Medical Research, NSW for providing us with galanin gene knock- out mice.



I am also thankful to Flinders Technologies, Flinders university of South Australia, Bio Innovation SA and Flinders Medical Centre Research Foundation for the financial support provided for this project.

I wish to thank my wife, family and friends for their patience, encouragement and tireless support during the time taken to complete these studies and thesis.

Finally, I would like to dedicate this work to my beloved mother Mrs. Suman Bhandari.

## ABBREVIATIONS

The following abbreviations are used throughout the text, figures and figure legends of this thesis.

ANOVA	Analysis of variance
AP	Acute pancreatitis
BP	Blood pressure
BSA	Bovine serum albumin
Ca <sup>++</sup>	Calcium
CCK	Cholecystokinin
CCK-8	Cholecystokinin octapeptide
CNS	Central nervous system
CVP	Central venous pressure
GAL-LI	Galanin- like immunoreactivity
GALR1	Galanin receptor 1
GALR2	Galanin receptor 2
GALR3	Galanin receptor 3
GMAP	Galanin message associated peptide
ICAM	Intercellular adhesion molecule
IL	Interleukin
IV	Intravenous
KO	Knock-out
LDF	Laser Doppler fluxmetry
MPO	Myeloperoxidase
NO	Nitric oxide
NOS	Nitric oxide synthase
NFK $\beta$	Nuclear factor kappa Beta
PD	Pancreatic duct
PDP	Pancreatic duct pressure
PVP	Pancreatic vascular perfusion
RNA	Ribonucleic acid

SEC	Secretin
SEM	Standard error of the mean
TNF	Tumour necrosis factor
VIP	Vasoactive intestinal polypeptide
WT	Wild type

## **STRUCTURE OF THESIS**

### **History of candidature**

My candidature for this thesis commenced in April 2004 as a full time student. The literature review was surveyed during 2004. During this year preliminary studies were performed based on the findings of my predecessor, Mark Brook-Smith. Based on these preliminary studies the overall hypothesis and specific hypotheses were defined. The experimental studies were performed initially in the possum during the later half of 2004 to early 2006. Then the studies were undertaken in the mouse from 2006 to mid 2007 to further test the hypothesis. Subsequently during 2007-2008, the thesis was compiled for submission.

### **Thesis chapters**

The structure of this thesis conforms to Flinders University guidelines. This thesis is presented in the following chapters.

Chapter 1 contains an overview of the relevant literature up to the time i completed experimental studies (mid 2007). The literature review has been updated to include key findings that aid in understanding of the pathophysiology of acute pancreatitis. Chapter 1 concludes with the presentation of general hypothesis, followed by the research aims.

Chapters 2-7 describe the experimental studies i.e. aims, methodology, analysis, statistical methods, results and discussion. Each chapter begins with a brief introduction.

Chapter 8 contains general discussion. The purpose of this chapter is to relate the findings to the original hypothesis. This section concludes with suggestions for future research.

**Location of figures**

To minimise disruption to the text, all figures are located near the end of each chapter.